Phu Quoc Le
Overview
Explore the profile of Phu Quoc Le including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
236
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Santoro C, Fuh B, Le P, Maes P, Berrueco R, Mingot-Castellano E, et al.
Eur J Haematol
. 2022 Oct;
110(1):77-87.
PMID: 36192847
Objectives: To report the final results of the 2-year TAURUS study, assessing weekly prophylaxis dosing regimens of octocog alfa (Kovaltry®/BAY 81-8973) used in standard clinical practice in patients with moderate-to-severe...
2.
van Overbeeke E, Hauber B, Michelsen S, Peerlinck K, Lambert C, Hermans C, et al.
Haemophilia
. 2021 Sep;
27(6):957-966.
PMID: 34472162
Objectives: The aim of the Patient preferences to Assess Value IN Gene therapies (PAVING) study was to investigate trade-offs that adult Belgian people with haemophilia (PWH) A and B are...
3.
Bellemans M, de Saint-Aubin de Somerhausen N, Le P
Case Rep Orthop
. 2021 Aug;
2021:8876584.
PMID: 34367707
Introduction: Osteoid osteoma is an uncommon, small, benign, self-limiting, and usually painful tumor of the skeleton. Diagnosis can be straightforward if seen in the usual locations as the femur and...
4.
LA C, Le P, Ferster A, Goffin L, Spruyt D, Lauwerys B, et al.
RMD Open
. 2021 Jun;
7(2).
PMID: 34108235
Introduction: In the management of juvenile idiopathic arthritis (JIA), there is a lack of diagnostic and prognostic biomarkers. This study assesses the use of serum calprotectin (sCal) as a marker...
5.
BAY 81-8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study
Santoro C, Fuh B, Le P, Maes P, Berrueco R, Mingot-Castellano E, et al.
Eur J Haematol
. 2020 Apr;
105(2):164-172.
PMID: 32259334
Objectives: To report interim data from TAURUS, a study assessing real-world prophylactic treatment with unmodified, full-length recombinant FVIII BAY 81-8973 (Kovaltry ; Bayer) indicated for haemophilia A. Methods: TAURUS (NCT02830477)...
6.
Rozen L, Noubouossie D, Dedeken L, Le P, Ferster A, Demulder A
J Clin Med
. 2019 Nov;
8(11).
PMID: 31717804
Several components of the clotting system are modified towards hypercoagulability in sickle cell disease (SCD). To date, hematopoietic stem cell transplantation (HSCT) is the only validated curative treatment of SCD....
7.
Dedeken L, Le P, Rozen L, El Kenz H, Huybrechts S, Devalck C, et al.
Transfusion
. 2018 Mar;
58(6):1356-1362.
PMID: 29574950
Background: Chronic transfusion in sickle cell disease (SCD) remains the gold standard therapy for stroke prevention and for patients with severe disease despite adequate hydroxyurea treatment. The aim of our...
8.
Sins J, Fijnvandraat K, Rijneveld A, Boom M, Kerkhoffs J, van Meurs A, et al.
Br J Haematol
. 2017 Jun;
182(3):444-448.
PMID: 28643376
No abstract available.
9.
Rozen L, Noubouossie D, Dedeken L, Huybrechts S, Le P, Ferster A, et al.
Pediatr Blood Cancer
. 2016 Sep;
64(2):294-301.
PMID: 27605400
Background: Asparaginase (Asp) and corticosteroid (CS) treatment in patients with acute lymphoblastic leukaemia (ALL) is associated with an increased risk of thrombotic events. Objective: Characterization of global haemostatic phenotypes of...
10.
Le P, Gulbis B, Dedeken L, Dupont S, Vanderfaeillie A, Heijmans C, et al.
Pediatr Blood Cancer
. 2015 Jul;
62(11):1956-61.
PMID: 26173735
Objective: To evaluate the survival of patients with sickle cell disease (SCD) recorded in the Belgian SCD Registry and to assess the impact of disease-modifying treatments (DMT). Method: The Registry...